

# **Cardiac Biomarkers Market by Type (Myocardial muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA)), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis) and Location of Testing (Point of care, Laboratory)- Global Opportunity Analysis and Industry Forecast, 2014 - 2020**

<https://marketpublishers.com/r/W786384189FEN.html>

Date: August 2015

Pages: 103

Price: US\$ 5,540.00 (Single User License)

ID: W786384189FEN

## **Abstracts**

The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment. Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state and used for diagnostic and prognostic purposes associated with heart. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infarction, congestive heart failure, acute coronary syndrome (ACS) among others. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA and few others.

Ability of cardiac biomarkers for accurate and rapid prediction of heart failure after the onset of chest pain has added boost to the market growth. In addition, promising features such as high accuracy, quick outcomes and economic pricing of cardiac point of care (POC) testing is driving the growth of cardiac biomarker market, globally. To keep the momentum of cardiac biomarker, the key manufacturers offers customized solutions. The commercial application of multi-menu options for cardiac testing using different combinations of cardiac biomarkers and target-oriented solutions are the key

opportunities of the cardiac biomarker market. However, limited specificity in some cases and side effects such as skeletal muscle injury are some of the factors restraining the growth cardiac biomarkers markets.

The Global cardiac biomarker market is segmented based on type, application, location of testing and geography. Based on cardiac biomarker type, the market is segmented into Creatine Kinase (CK-MB), Troponins T and I, myoglobin, BNP, IMA and others. Troponins I and T are the highest revenue-generating segment in the overall cardiac biomarker market due to its prodigious specificity and its ability to accurately detect the cardiac events of Acute Coronary Syndrome (ACS).

Based on application, the market is segmented into myocardial infarction, congestive heart failure, Acute Coronary Syndrome, atherosclerosis and others. Myocardial infarction (MI) holds the highest market share in the global cardiac biomarker market followed by Acute Coronary Syndrome (ACS) due to the highest prevalence rate among cardiovascular diseases (CVDs). The location of testing segment is classified as point of care testing and laboratory testing. Doctors and clinicians largely prefer point of care cardiac testing for quick monitoring patients with chest pain in an emergency care unit, therefore, accounting the fastest CAGR. However, laboratory testing is generating larger revenue in comparison to point of care testing.

Based on geography, the global cardiac biomarker market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America leads the global cardiac biomarker market, owing to the high demand for cardiac testing, high CVD prevalence rate and growing awareness towards cardiac diagnostics solutions. Asia-Pacific is growing at the fastest CAGR due to the modernization, increasing disposable incomes and rising affordability for the advanced cardiac treatments.

Key companies profiled in this market include Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, Alere Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, BioMerieux, Randox laboratories, Beckman Coulter and Thermo Fisher Scientific. Product launch and technological advancements are the few strategies adopted by the key players of global cardiac biomarker market. The companies are currently focusing on innovative technologies such as automated, multi-assay using combinations of cardiac biomarkers and point-of-care cardiac biomarker devices.

## **KEY BENEFITS:**

Extensive coverage of the global cardiac biomarker market including drivers, restraints and opportunities would help professionals to better understand the market behaviour

Country level analysis has been done to provide micro market sizing of cardiac biomarker in different regions

The market estimations are made in the report by conducting high-end analysis of the key market segments for the period of 2014-2020

A comprehensive analysis of the market scenario in terms of types, applications, location of testing and geography helps identify the growth opportunities in the global cardiac biomarker market

The market attractiveness analysis for the Global cardiac biomarker market provides strategic assistance to the decision makers

Key market players within the global cardiac biomarker market are profiled in the report and their strategies are analysed thoroughly, which helps in understanding competitive outlook of this market

## **KEY MARKET SEGMENTS:**

Global Cardiac biomarker market is segmented into type, application, location of testing and geography.

Global Cardiac Biomarker Market – By Type

Myocardial muscle Creatine Kinase (CK-MB)

Troponins (T and I)

Myoglobin

Brain Natriuretic Peptide (BNPs) or NT-proBNP

Ischemia Modified Albumin (IMA)

Others

Global Cardiac Biomarker Market – By Application

Myocardial Infarction

Congestive Heart Failure

Acute Coronary Syndrome

Atherosclerosis

Others

### Global Cardiac Biomarker Market – By Location of testing

Point of care testing

Laboratory testing

### Global Cardiac Biomarker Market – By Geography

North America

U.S.

Canada

Mexico

Europe

France

Germany

U.K.

Asia-Pacific

Japan

India

China

Australia

Others

LAMEA

Latin America

Middle East

Africa

## Contents

### CHAPTER 1 INTRODUCTION

- 1.1 Report description
- 1.2 Key Benefits
- 1.3 Key market segments
- 1.4 Research methodology
  - 1.4.1 Secondary research
  - 1.4.2 Primary research
  - 1.4.3 Analyst tools and models

### CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 CXO perspective
- 2.2 Market beyond what to expect by 2025 (\$Million)
  - 2.2.1 Moderate growth scenario
  - 2.2.2 Rapid growth scenario
  - 2.2.3 Diminishing growth scenario

### CHAPTER 3 MARKET OVERVIEW

- 3.1 Market Definition and Scope
- 3.2 Biomarker diagnosis vs. conventional diagnosis
- 3.3 Assessment of key advantages and buying criteria for diagnostic biomarkers
  - 3.3.1 Early diagnosis
  - 3.3.2 Tissue specific diagnosis
  - 3.3.3 Reduce clinical trials
  - 3.3.4 Risk assessments
  - 3.3.5 Consistent output
- 3.4 Key trends impacting the Cardiac biomarker market
  - 3.4.1 Development of high sensitive biomarkers for risk stratification
  - 3.4.2 Technological advancements in the cardiac biomarkers: Serum based biomarkers
  - 3.4.3 Increasing demand for point of care cardiac diagnostics
- 3.5 Key Findings
  - 3.5.1 Top Factors Impacting
  - 3.5.2 Top Investment Pockets
  - 3.5.3 Top winning strategies

- 3.6 Government Regulations and reimbursement
- 3.7 Reimbursement scenario
- 3.8 Porters five force Analysis
  - 3.8.1 Bargaining power of suppliers
  - 3.8.2 Bargaining power of buyers
  - 3.8.3 Threats from substitute products
  - 3.8.4 Threat from new entrants
  - 3.8.5 Industry rivalry
- 3.9 Value chain analysis
- 3.10 Clinical Trials
- 3.11 Patent Analysis
- 3.12 Market Share Analysis, 2014
- 3.13 Market Dynamics
  - 3.13.1 Drivers
    - 3.13.1.1 Increasing prevalence of cardiovascular diseases
    - 3.13.1.2 Cost effective
    - 3.13.1.3 Non-invasive
    - 3.13.1.4 Accuracy prediction
    - 3.13.1.5 Assistant in clinical trials
    - 3.13.1.6 Multi-marker application
    - 3.13.1.7 Technological advancements using cardiac biomarkers combinations
    - 3.13.1.8 Increasing point of care (POC) testing
  - 3.13.2 Restraints
    - 3.13.2.1 Government Regulation
    - 3.13.2.2 Conformation in result
    - 3.13.2.3 Complex process
  - 3.13.3 Opportunities
    - 3.13.3.1 Personalized medicine
    - 3.13.3.2 Point of care (POCT) testing using cardiac biomarkers
    - 3.13.3.3 Future DEVELOPMENTS IN novel cardiac biomarkers

## **CHAPTER 4 GLOBAL CARDIAC BIOMARKERS MARKET BY TYPE, 2014-2020**

- 4.1.1 Introduction
- 4.1.2 Key market trends
- 4.1.3 Key growth factors and opportunities
  - 4.1.3.1 Characteristics of cardiac biomarkers include:
- 4.1.4 Market size and forecast
- 4.2 Creatine Kinase (CK-MB)

- 4.2.1 Key market trends
- 4.2.2 Key growth factors and opportunities
- 4.2.3 Market size and forecast
- 4.3 Troponins(T,I)
  - 4.3.1 Key market trends
  - 4.3.2 Key growth factors and opportunities
  - 4.3.3 Market size and forecast
- 4.4 Myoglobin
  - 4.4.1 Key market trends
  - 4.4.2 Key growth factors and opportunities
  - 4.4.3 Market size and forecast
- 4.5 Natriuretic peptides (BNP and NT-proBNP)
  - 4.5.1 Key market trends
  - 4.5.2 Key growth factors and opportunities
  - 4.5.3 Market size and forecast
- 4.6 Ischemia Modified Albumin
  - 4.6.1 Key market trends
  - 4.6.2 Key growth factors and opportunities
  - 4.6.3 Market size and forecast
- 4.7 Others
  - 4.7.1 Key market trends
  - 4.7.2 Key growth factors and opportunities
  - 4.7.3 Market size and forecast

## **CHAPTER 5 GLOBAL CARDIAC BIOMARKERS MARKET BY APPLICATION, 2014-2020**

- 5.1 Myocardial Infarction
  - 5.1.1 Market size and forecast
- 5.2 Congestive Heart Failure
  - 5.2.1 Market size and forecast
- 5.3 Acute Coronary Syndrome
  - 5.3.1 Market size and forecast
- 5.4 Atherosclerosis
  - 5.4.1 Market size and forecast
- 5.5 Others
  - 5.5.1 Market size and forecast

## **CHAPTER 6 GLOBAL CARDIAC BIOMARKERS MARKET BY LOCATION OF**

*Cardiac Biomarkers Market by Type (Myocardial muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin,...*



## **TESTING, 2014-2020**

### 6.1 Point of care testing

#### 6.1.1 Market size and forecast

### 6.2 Laboratory testing

#### 6.2.1 Market size and forecast

## **CHAPTER 7 GLOBAL CARDIAC BIOMARKER MARKET BY GEOGRAPHY, 2014-2020**

### 7.1 North America

#### 7.1.1 Key market trends

#### 7.1.2 Key growth factors and opportunities

#### 7.1.3 Market size and forecast

#### 7.1.4 United States

#### 7.1.5 Canada

#### 7.1.6 Mexico

### 7.2 Europe

#### 7.2.1 Key market trends

#### 7.2.2 Key growth factors and opportunities

#### 7.2.3 Market size and forecast

#### 7.2.4 United Kingdom

#### 7.2.5 France

#### 7.2.6 Germany

#### 7.2.7 Others

### 7.3 Asia-Pacific

#### 7.3.1 Key market trends

#### 7.3.2 Key growth factors and opportunities

#### 7.3.3 Market size and forecast

#### 7.3.4 China

#### 7.3.5 India

#### 7.3.6 Australia

#### 7.3.7 Japan

#### 7.3.8 Rest of Asia Pacific Countries

### 7.4 LAMEA

#### 7.4.1 Key market trends

#### 7.4.2 Key growth factors and opportunities

#### 7.4.3 Market size and forecast

#### 7.4.4 Latin America

7.4.5 Middle East

7.4.6 Africa

## **CHAPTER 8 COMPANY PROFILES**

### 8.1 Abbott laboratories

8.1.1 Company Overview

8.1.2 Company snapshot

8.1.3 Financial performance

8.1.4 Operating segment overview

8.1.5 Strategic moves and developments

8.1.6 SWOT analysis of Abbott Laboratories

### 8.2 Alere Inc.

8.2.1 Company overview

8.2.2 Alere Inc. snapshot

8.2.3 Operating business segments

8.2.4 Business performance

8.2.5 Key Strategies and developments

8.2.6 SWOT analysis of Alere Inc.

### 8.3 Siemens Healthcare

8.3.1 Company overview

8.3.2 Company snapshot

8.3.3 Financial performance

8.3.4 SWOT analysis of Siemens Healthcare

### 8.4 Roche Diagnostics Corporation

8.4.1 Company overview

8.4.2 Roche Diagnostics snapshot

8.4.3 Operating business segments

8.4.4 Financial performance

8.4.5 Strategic moves and developments

8.4.6 SWOT analysis Roche Diagnostics

### 8.5 Beckman Coulter

8.5.1 Company overview

8.5.2 Company Snapshot

8.5.3 Strategies and Development

8.5.4 Swot Analysis of Beckman Coulter, Inc.

### 8.6 Becton, Dickinson And Co.

8.6.1 Company overview

8.6.2 Becton Dickinson and Company snapshot

- 8.6.3 Operating Business Segments
- 8.6.4 Business performance
- 8.6.5 Key Strategies and development
- 8.6.6 SWOT analysis of Becton Dickinson and Company
- 8.7 Thermo Fisher Scientific
  - 8.7.1 Company profile
  - 8.7.2 Company snapshot
  - 8.7.3 Business performance
  - 8.7.4 Strategic moves and developments
  - 8.7.5 SWOT analysis & strategic conclusions
- 8.8 BioMerieux
  - 8.8.1 Company overview
  - 8.8.2 BioMerieux snapshot
  - 8.8.3 Business performance
  - 8.8.4 Operating business segments
  - 8.8.5 SWOT analysis of BioMerieux
- 8.9 Bio-Rad Laboratories
  - 8.9.1 Company profile
  - 8.9.2 Company snapshot
  - 8.9.3 Business performance
  - 8.9.4 Strategic moves and developments
  - 8.9.5 SWOT analysis & strategic conclusions
- 8.10 Randox laboratories
  - 8.10.1 Company overview
  - 8.10.2 Randox Laboratories. snapshot
  - 8.10.1 Strategic moves and developments
  - 8.10.2 SWOT analysis of Randox Laboratories

## List Of Tables

### LIST OF TABLES

TABLE 1 GLOBAL CARDIAC BIOMARKER MARKET REVENUE, BY GEOGRAPHY, 2014-2020 (\$MILLION)

TABLE 2 MODERATE GROWTH RATE SCENARIO OF CARDIAC BIOMARKER MARKET, 2020-2025 (\$MILLION)

TABLE 3 RAPID GROWTH RATE SCENARIO OF CARDIAC BIOMARKER MARKET, 2020-2025 (\$MILLION)

TABLE 4 DIMINISHING GROWTH RATE SCENARIO OF CARDIAC BIOMARKER MARKET, 2020-2025 (\$MILLION)

TABLE 5 CONVENTIONAL DIAGNOSTICS VERSUS DIAGNOSTIC BIOMARKER TECHNIQUES

TABLE 6 TOP WINNING STRATEGIES

TABLE 7 CARDIAC BIOMARKERS CURRENTLY IN USE

TABLE 8 CHARACTERISTICS OF CARDIAC BIOMARKER

TABLE 9 GLOBAL CARDIAC BIOMARKER MARKET BY TYPE, 2014 - 2020 (\$MILLION)

TABLE 10 GLOBAL CARDIAC BIOMARKER CREATINE KINASE MARKET BY GEOGRAPHY, 2014 - 2020 (\$MILLION)

TABLE 11 GLOBAL CARDIAC BIOMARKER TROPONINS (T,I) MARKET BY GEOGRAPHY, 2014 - 2020 (\$MILLION)

TABLE 12 GLOBAL CARDIAC BIOMARKER MYOGLOBIN MARKET BY GEOGRAPHY, 2014 - 2020 (\$MILLION)

TABLE 13 GLOBAL CARDIAC BIOMARKER NATRIURETIC PEPTIDE (BNP AND NT-PROBNP) MARKET BY GEOGRAPHY, 2014 - 2020 (\$MILLION)

TABLE 14 GLOBAL CARDIAC BIOMARKER ISCHEMIA MODIFIED ALBUMIN MARKET BY GEOGRAPHY, 2014 - 2020 (\$MILLION)

TABLE 15 GLOBAL CARDIAC BIOMARKER OTHER TYPES MARKET BY GEOGRAPHY, 2014 - 2020 (\$MILLION)

TABLE 16 GLOBAL CARDIAC BIOMARKER MARKET BY APPLICATIONS, 2014-2020 (\$MILLION)

TABLE 17 CARDIAC BIOMARKERS USED FOR MONITORING PATIENTS WITH MYOCARDIAL INFRACTIONS

TABLE 18 GLOBAL CARDIAC BIOMARKER MYOCARDIAL INFARCTION APPLICATION MARKET BY GEOGRAPHY, 2014 - 2020 (\$MILLION)

TABLE 19 GLOBAL CARDIAC BIOMARKER CONGESTIVE HEART FAILURE APPLICATION MARKET BY GEOGRAPHY, 2014 - 2020 (\$MILLION)

TABLE 20 GLOBAL CARDIAC BIOMARKER ACUTE CORONARY SYNDROME APPLICATION MARKET BY GEOGRAPHY, 2014 - 2020 (\$MILLION)

TABLE 21 GLOBAL CARDIAC BIOMARKER ATHEROSCLEROSIS APPLICATION MARKET BY GEOGRAPHY, 2014 - 2020 (\$MILLION)

TABLE 22 GLOBAL CARDIAC BIOMARKER OTHERS APPLICATION MARKET BY GEOGRAPHY, 2014 - 2020 (\$MILLION)

TABLE 23 GLOBAL CARDIAC BIOMARKER MARKET BY LOCATION OF TESTING, 2014-2020 (\$MILLION)

TABLE 24 GLOBAL CARDIAC BIOMARKER POINT OF CARE TESTING MARKET BY GEOGRAPHY, 2014-2020 (\$MILLION)

TABLE 25 GLOBAL CARDIAC BIOMARKER LABORATORY TESTING MARKET BY GEOGRAPHY, 2014-2020 (\$MILLION)

TABLE 26 GLOBAL CARDIAC BIOMARKER MARKET BY GEOGRAPHY, 2014 2020 (\$MILLION)

TABLE 27 NORTH AMERICA CARDIAC BIOMARKER MARKET BY COUNTRY, 2014 2020 (\$MILLION)

TABLE 28 UNITED STATES CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 (\$MILLION)

TABLE 29 CANADA CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 (\$MILLION)

TABLE 30 MEXICO CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 (\$MILLION)

TABLE 31 EUROPE CARDIAC BIOMARKER MARKET BY COUNTRY, 2014 2020 (\$MILLION)

TABLE 32 UNITED KINGDOM CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 (\$MILLION)

TABLE 33 FRANCE CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 (\$MILLION)

TABLE 34 GERMANY CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 (\$MILLION)

TABLE 35 OTHER EUROPE CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 (\$MILLION)

TABLE 36 ASIA-PACIFIC CARDIAC BIOMARKER MARKET BY COUNTRY, 2014 2020 (\$MILLION)

TABLE 37 CHINA CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 (\$MILLION)

TABLE 38 INDIA CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 (\$MILLION)

TABLE 39 AUSTRALIA CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 (\$MILLION)

TABLE 40 JAPAN CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 (\$MILLION)

TABLE 41 OTHER ASIA-PACIFIC CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 (\$MILLION)

TABLE 42 LAMEA CARDIAC BIOMARKER MARKET BY COUNTRY, 2014 2020 (\$MILLION)

TABLE 43 LATIN AMERICA CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 (\$MILLION)

TABLE 44 MIDDLE EAST CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 (\$MILLION)

TABLE 45 AFRICA CARDIAC BIOMARKER MARKET BY TYPE, 2014 2020 (\$MILLION)

TABLE 46 ABBOTT LABORATORIES BUSINESS SNAPSHOT

TABLE 47 ABBOTT LABORATORIES OPERATING SEGEMENTS

TABLE 48 ALERE INC. COMPANY SNAPSHOT

TABLE 49 ALERE INC. OPERATING SEGEMENTS

TABLE 50 COMPANY SNAPSHOT OF SIEMENS HEALTHCARE

TABLE 51 COMPANY SNAPSHOT OF ROCHE DIAGNOSTICS

TABLE 52 ROCHE DIAGNOSTICS OPERATING SEGEMENTS

TABLE 53 SNAPSHOT OF BECKMAN COULTER, INC

TABLE 54 SWOT ANALYSIS OF BECKMAN COULTER, INC

TABLE 55 BECTON DICKINSON AND COMPANY SNAPSHOT

TABLE 56 BECTON DICKINSON AND COMPANY OPERATING SEGEMENTS

TABLE 57 THERMO FISHER SCIENTIFIC INC. BUSINESS SNAPSHOT

TABLE 58 BIOMERIEUX COMPANY SNAPSHOT

TABLE 59 BIOMERIEUX OPERATING SEGEMENTS

TABLE 60 BIO-RAD LABORATORIES BUSINESS SNAPSHOT

TABLE 61 RANDOX LABORATORIES COMPANY SNAPSHOT

## List Of Figures

### LIST OF FIGURES

- FIG. 1 IMPACT ANALYSIS OF MODERATE GROWTH SCENARIO (2020-2025)
- FIG. 2 IMPACT ANALYSIS OF RAPID GROWTH SCENARIO (2020-2025)
- FIG. 3 IMPACT ANALYSIS OF DIMINISHING GROWTH SCENARIO (2020-2025)
- FIG. 4 TOP IMPACTING FACTORS FOR CARDIAC BIOMARKER MARKET 2014-2020
- FIG. 5 TOP INVESTMENT POCKETS OF GLOBAL CARDIAC BIOMARKERS MARKET
- FIG. 6 TOP WINNING STRATEGIES IN GLOBAL CARDIAC BIOMARKERS MARKET 2011-2014
- FIG. 7 PORTER'S FIVE FORCES MODEL
- FIG. 8 VALUE CHAIN
- FIG. 9 PATENT ANALYSIS BY GEOGRAPHY (2012-2015)
- FIG. 10 MARKET SHARE ANALYSIS, 2014)
- FIG. 11 SCHEMATIC REPRESENTATION OF CARDIOVASCULAR EVENTS AND RESPECTIVE CARDIAC BIOMARKERS USED FOR DIAGNOSIS AND PROGNOSIS
- FIG. 12 REVENUE GENERATED BY ABBOTT LABORATORIES. (2012-2014)
- FIG. 13 ABBOTT LABORATORIES, INC. FINANCIAL REVENUES BY BUSINESS UNITS
- FIG. 14 ABBOTT LABORATORIES, INC. FINANCIAL REVENUES BY GEOGRAPHY (2014)
- FIG. 15 SWOT ANALYSIS OF ABBOTT LABORATORIES INC.
- FIG. 16 KEY FINANCIALS OF ALERE INC. BY OPERATING SEGMENTS (2013)
- FIG. 17 KEY FINANCIALS OF ALERE INC. BY GEOGRAPHY (2013)
- FIG. 18 KEY FINANCIALS OF ALERE INC. BY THERAPEUTIC AREA (2013)
- FIG. 19 SWOT ANALYSIS OF ALERE INC.
- FIG. 20 KEY FINANCIALS OF SIEMENS HEALTHCARE REVENUE, 2011-2014, \$MILLION
- FIG. 21 KEY FINANCIALS OF SIEMENS HEALTHCARE REVENUES BY SEGMENT 2014
- FIG. 22 KEY FINANCIALS OF SIEMENS HEALTHCARE REVENUES BY GEOGRAPHY 2014
- FIG. 23 SWOT ANALYSIS OF SIEMENS HEALTHCARE
- FIG. 24 KEY FINANCIALS OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)
- FIG. 25 SWOT ANALYSIS OF ROCHE DIAGNOSTICS
- FIG. 26 KEY FINANCIALS OF BECTON DICKINSON AND COMPANY BY SEGMENT (2013)

FIG. 27 KEY FINANCIALS OF BECTON DICKINSON AND COMPANY BY GEOGRAPHY (2013)

FIG. 28 SWOT ANALYSIS OF BECTON DICKINSON AND COMPANY

FIG. 29 THERMO FISHER SCIENTIFIC INC. FINANCIAL REVENUES BY BUSINESS UNITS (2012)

FIG. 30 THERMO FISHER SCIENTIFIC INC. FINANCIAL REVENUES BY GEOGRAPHIC AREAS (2012)

FIG. 31 SWOT ANALYSIS OF THERMO FISHER SCIENTIFIC INC.

FIG. 32 KEY FINANCIALS OF BIOMERIEUX BY APPLICATIONS (2014)

FIG. 33 KEY FINANCIALS OF BIOMERIEUX BY GEOGRAPHY (2014)

FIG. 34 SWOT ANALYSIS OF BIOMERIEUX

FIG. 35 KEY FINANCIALS OF BIO-RAD LABORATORIES REVENUE, 2012-2014, \$MILLION

FIG. 36 BIO-RAD LABORATORIES FINANCIAL REVENUES BY BUSINESS UNITS (2014)

FIG. 37 BIO-RAD LABORATORIES FINANCIAL REVENUES BY GEOGRAPHY (2014)

FIG. 38 SWOT ANALYSIS OF BIO-RAD LABORATORIES

FIG. 39 SWOT ANALYSIS OF RANDOX LABORATORIES



## I would like to order

Product name: Cardiac Biomarkers Market by Type (Myocardial muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA)), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis) and Location of Testing (Point of care, Laboratory)- Global Opportunity Analysis and Industry Forecast, 2014 - 2020

Product link: <https://marketpublishers.com/r/W786384189FEN.html>

Price: US\$ 5,540.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/W786384189FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970